Epidemiology of doublet/multiplet mutations in lung cancers: Evidence that a subset arises arises by chronocoordinate events

PLoS ONE

Volumn 3, Issue 11, 2008, Pages

  Chen, Zhenbin ^a   Feng, Jinong ^a   Buzin, Carolyn H ^a   Sommer, Steve S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ARTICLE; CANCER RISK; DOUBLET MUTATION; ETHNICITY; FRAMESHIFT MUTATION; GENE CLUSTER; GENE FREQUENCY; GENE MUTATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; MULTIPLET MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MUTATION; SEQUENCE ANALYSIS; SEX DIFFERENCE; SMOKING HABIT; AGED; ANIMAL; FEMALE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; RISK FACTOR; TUMOR SUPPRESSOR GENE;

AGED; ANIMALS; DNA MUTATIONAL ANALYSIS; FEMALE; FRAMESHIFT MUTATION; GENES, ERBB-1; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 56649109612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003714     Document Type: Article

References (31)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
3. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
4. Bielas JH, Loeb LA (2005) Mutator phenotype in cancer: timing and perspectives. Environ Mol Mutagen 45: 206-213.
5. Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61: 3230-3239.
6. Loeb LA, Loeb KR, Anderson JP (2003) Multiple mutations and cancer. Proc Natl Acad Sci U S A 100: 776-781.
7. Tomlinson I, Novelli M, Bodmer WF (1996) The mutation rate and cancer. Proc Natl Acad Sci U S A 93: 14800-14803.
8. Tomlinson I, Bodmer W (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nature Medicine 5: 11-13.
9. Wang J, Gonzalez KD, Scaringe WA, Tsai K, Liu N, et al. (2007) Evidence for mutation showers. Proc Natl Acad Sci U S A 104: 8403-8408.
10. Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, et al. (2008) EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene 27: 4336-4343.
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
13. Hill KA, Wang J, Farwell KD, Scaringe WA, Sommer SS (2004) Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency. Mutat Res 554: 223-240.
14. Buettner VL, Hill KA, Scaringe WA, Sommer SS (2000) Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events. Mutat Res 452: 219-229.
15. Halangoda A, Still JG, Hill KA, Sommer SS (2001) Spontaneous microdeletions and microinsertions in a transgenic mouse mutation detection system: analysis of age, tissue, and sequence specificity. Environ Mol Mutagen 37: 311-323.
16. Sommer SS, Scaringe WA, Hill KA (2001) Human germline mutation in the factor IX gene. Mutat Res 487: 1-17.
17. Cooper DN, Krawczak M (1993) Human Gene Mutation. Oxford, England: Bios Scientific Publishers.
18. Roberts RG, Gardner RJ, Bobrow M (1994) Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat 4: 1-11.
19. Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, et al. (2006) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97: 753-759.
20. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, et al. (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653.
21. Sommer SS (1990) Mutagen test. Nature 346: 22-23.
22. Hill KA, Sommer SS (2002) p53 as a mutagen test in breast cancer. Environ Mol Mutagen 39: 216-227.
23. Drake JW, Bebenek A, Kissling GE, Peddada S (2005) Clusters of mutations from transient hypermutability. Proc Natl Acad Sci U S A 102: 12849-12854.
24. Drake JW (2007) Too many mutants with multiple mutations. Crit Rev Biochem Mol Biol 42: 247-258.
25. Sommer SS, Cohen JE (1980) The size distributions of proteins, mRNA, and nascent transcripts. J Mol Evol 15: 37-57.
26. Strauss BS (1997) Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18: 1445-1452.
27. Strauss BS (2000) Role in tumorigenesis of silent mutations in the TP53 gene. Mutat Res 457: 93-104.
28. Hill KA, Wang J, Farwell KD, Sommer SS (2003) Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity. Mutat Res 534: 173-186.
29. Buettner VL, Hill KA, Halangoda A, Sommer SS (1999) Tandem-based mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age. Environ Mol Mutagen 33: 320-324.
30. Ketterling RP, Drost JB, Scaringe WA, Liao D, Liu J-Z, et al. (1999) Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. Hum Mutat 13: 221-231.
31. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, et al. (2007) Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28: 760-770.